BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

A Cherry in MorphoSys’ hunt for new techMorphoSys AG (Xetra:MOR; NASDAQ:MOR) entered an exclusive licensing agreement with University Hospital Würzburg spinout Cherry Biolabs GmbH for access to its Hemibody platform to discover and develop T...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

...UCB buying Engage for $125M UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler...
...Inc. Melinta Therapeutics Inc. McGill University Jounce Therapeutics Inc. Bristol Myers Squibb Co. Genmab A/S Merck & Co. Inc. UCB S.A. Apeiron Biologics AG Engage Therapeutics Inc. Leukocyte...
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues....
BioCentury | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
BioCentury | Sep 29, 2017
Financial News

Engage, Integra raise venture financings

...Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture...
...of Jerusalem . The firm's portfolio includes Alzheimer's disease company Avraham Pharmaceuticals Ltd. (Yavneh, Israel). Engage Therapeutics Inc....
...Holdings, Jerusalem, Israel Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Avraham Pharmaceuticals Ltd. Grupo Ferrer Internacional S.A. Hebrew University of Jerusalem GABA receptor Engage Therapeutics Inc....
BioCentury | Sep 28, 2017
Financial News

Venture roundup: Engage, Integra

...On Wednesday, epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel...
...The firm's portfolio includes Alzheimer's disease company Avraham Pharmaceuticals Ltd. (Yavneh, Israel). Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Ferrer Engage Therapeutics Inc....
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
Items per page:
1 - 7 of 7
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

A Cherry in MorphoSys’ hunt for new techMorphoSys AG (Xetra:MOR; NASDAQ:MOR) entered an exclusive licensing agreement with University Hospital Würzburg spinout Cherry Biolabs GmbH for access to its Hemibody platform to discover and develop T...
BioCentury | Jun 6, 2020
Product Development

June 5 Quick Takes: Merck, Tetraphase-Melinta, Apeiron, Neurasic, Jounce, Genmab-J&J

...UCB buying Engage for $125M UCB S.A. (Euronext:UCB) acquired Engage Therapeutics Inc. Friday, gaining Staccato alprazolam, a drug-inhaler...
...Inc. Melinta Therapeutics Inc. McGill University Jounce Therapeutics Inc. Bristol Myers Squibb Co. Genmab A/S Merck & Co. Inc. UCB S.A. Apeiron Biologics AG Engage Therapeutics Inc. Leukocyte...
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues....
BioCentury | May 4, 2018
Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...
BioCentury | Sep 29, 2017
Financial News

Engage, Integra raise venture financings

...Epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel) announced venture...
...of Jerusalem . The firm's portfolio includes Alzheimer's disease company Avraham Pharmaceuticals Ltd. (Yavneh, Israel). Engage Therapeutics Inc....
...Holdings, Jerusalem, Israel Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Avraham Pharmaceuticals Ltd. Grupo Ferrer Internacional S.A. Hebrew University of Jerusalem GABA receptor Engage Therapeutics Inc....
BioCentury | Sep 28, 2017
Financial News

Venture roundup: Engage, Integra

...On Wednesday, epilepsy play Engage Therapeutics Inc. (Summit, N.J.) and life science investment company Integra Holdings (Jerusalem, Israel...
...The firm's portfolio includes Alzheimer's disease company Avraham Pharmaceuticals Ltd. (Yavneh, Israel). Jennie Walters Staccato alprazolam Alexza Pharmaceuticals Inc. Ferrer Engage Therapeutics Inc....
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

No longer content with a walk-on role as research subjects, and empowered by access to more information and the necessity of shouldering a bigger share of the healthcare bill, patients are demanding a speaking role...
Items per page:
1 - 7 of 7